A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-12-31

Study Completion Date

2017-04-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the differential expression of AD biomarkers in serum, plasma, and skin biopsies from both lesional and non-lesional skin in moderate to severe AD patients in the presence of TCS and after withdrawal from TCS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

NCT01756898

Atopic Dermatitis

COMPLETED PHASE2

Targeted Investigation of Microbiome Elimination

NCT05177328

Atopic Dermatitis

TERMINATED PHASE1

Topical Steroid Formulation and Wet Wraps

NCT02680301

Dermatitis, Atopic

COMPLETED PHASE4

A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis

NCT00106496

Dermatitis, Atopic

COMPLETED PHASE4

Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis

NCT03233529

Dermatitis, Atopic

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This exploratory study consists of four visits to the investigator site post screening: at Weeks 0 (baseline), 2, 6 and 8 (Figure 1). At the first visit (baseline), patients who have met the screening eligibility criteria will be started on a stable TCS regimen for a total of two weeks. At the second visit (Week 2) following two weeks of therapy on stable TCS, patients will stop TCS and blood, serum, plasma and two 6mm punch biopsies (one lesional (L) and one non-lesional (NL) skin) will be obtained. At the third visit (Week 6), after four weeks receiving no TCS, the same sample collections will be repeated and the patients will then enter a two week safety follow up. At the end of the safety follow up (last visit, Week 8) and after obtaining written informed consent by the patient, blood, serum and plasma samples mav be collected.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dermatitis, Atopic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Open label

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment

Topical Triamcinolone 0.1% ointment will be provided for twice daily application, during treatment periods.

Group Type EXPERIMENTAL

Triamcinolone 0.1%

Intervention Type DRUG

Topical ointment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Triamcinolone 0.1%

Topical ointment

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Triamcinolone 0.1% ointment

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female patients 18-75 years of age
2. AD diagnosed by the Rajka/Hanifin criteria at the time of screening and that has been present for at least 1 year
3. History of inadequate response to a stable regimen of TCS for 1 month (in the 3 months immediately preceding the screening visit) as treatment for their AD
4. Eczema Area and Severity Index (EASI) score ≥ 14 at the screening and baseline visits
5. Investigator's Global Assessment (IGA; 5-point) score ≥ 3 at the screening and baseline visits
6. ≥10% body surface area involvement by AD
7. A washout period prior to screening for those patients who have previously received the following medications:

* Cyclosporine/Oral Steroids/Imuran/Mycophenolate Mofetil/Other systemic immunosuppressants: 4 weeks
* Phototherapy: 4 weeks
* Biologics: 5 half lives of the drug

Exclusion Criteria

1. Evidence of other concomitant skin conditions (e.g., psoriasis or contact dermatitis)
2. Use of topical calcineurin inhibitors within 4 weeks of screening
3. Hypersensitivity to TCS or to any other ingredients contained by the emollient or TCS product used during the study
4. Evidence of active skin infection at screening or baseline visit
5. Evidence or history of active or latent infections such as tuberculosis or hepatitis C
6. Patient clinical condition is not appropriate for treatment with protocol prescribed TCS
7. Use of an investigational agent within 4 weeks prior to screening or within 5 half-lives of the investigational agent, whichever is longer
8. Use of a tanning booth/parlor within 4 weeks before the baseline visit
9. Use of any anti-histamine medication within 4 weeks before the baseline visit.
10. History of any condition (e.g. bleeding diathesis) that may predispose the patient to complications associated with the planned skin biopsy procedures
11. Known current malignancy or current evaluation for a potential malignancy, including basal or squamous cell carcinoma of the skin or carcinoma in situ
12. Other clinically significant medical disease that is uncontrolled despite treatment that is likely, in the opinion of the investigator, to impact the patient's ability to participate in the study or to impact the study pharmacodynamic (PD), or safety assessments
13. Unwillingness or inability to comply with the study protocol for any other reason.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No